Schizophrenia trials have been too small, short and exclusionary, leaving the most disabled patients under-represented and key outcomes neglected. Future research should match the illness burden through sustained funding, representative recruitment, multidomain assessment, and adaptive, platform and SMART designs that test treatments efficiently and produce evidence relevant to patients' lives.
Journal article
2026-05-15T00:00:00+00:00
1 - 4
3
Schizophrenia, negative symptoms, platform studies, treatment-resistant, trial design